ERBB2 and breast carcinoma: Interestingly, we identified a key network centered on ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), commonly known as HER2, widely recognized as a breast cancer biomarker and a relevant player in gynecologic malignancies (Erickson et al., 2020).